Changes in cardiac and vascular haemodynamics as potential mediators of improvements in cardiovascular and kidney outcomes with empagliflozin in type 2 diabetes.

[1]  Shenghua Zhou,et al.  Emerging Roles of Sodium Glucose Cotransporter 2 (SGLT-2) Inhibitors in Diabetic Cardiovascular Diseases: Focusing on Immunity, Inflammation and Metabolism , 2022, Frontiers in Pharmacology.

[2]  P. Ponikowski,et al.  Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure. , 2021, Journal of the American College of Cardiology.

[3]  R. Collins,et al.  Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis , 2021, The Lancet.

[4]  C. Wanner,et al.  Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME® trial. , 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  B. Zinman,et al.  Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose co-transporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. , 2020, Kidney international.

[6]  W. März,et al.  Association of double product and pulse pressure with cardiovascular and all‐cause mortality in the LURIC study , 2020, Journal of clinical hypertension.

[7]  J. McMurray,et al.  Dapagliflozin in Patients with Chronic Kidney Disease. , 2020, The New England journal of medicine.

[8]  P. Ponikowski,et al.  Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. , 2020, The New England journal of medicine.

[9]  Changjiang Zhang,et al.  SGLT2i: beyond the glucose-lowering effect , 2020, Cardiovascular Diabetology.

[10]  M. Woodward,et al.  Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes. , 2020, JACC. Heart failure.

[11]  Akshay S. Desai,et al.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.

[12]  M. Landray,et al.  The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study , 2018, Clinical kidney journal.

[13]  M. Cooper,et al.  Cardiovascular Disease and Diabetic Kidney Disease. , 2018, Seminars in nephrology.

[14]  B. Zinman,et al.  How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial , 2017, Diabetes Care.

[15]  B. Zinman,et al.  Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial , 2017, ESC heart failure.

[16]  R. Townsend,et al.  Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis , 2017, Cardiovascular Diabetology.

[17]  John M Lachin,et al.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. , 2016, The New England journal of medicine.

[18]  Dahai Yu,et al.  Interaction between Mean Arterial Pressure and HbA1c in Prediction of Cardiovascular Disease Hospitalisation: A Population-Based Case-Control Study , 2016, Journal of diabetes research.

[19]  B. Zinman,et al.  Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial , 2016, European heart journal.

[20]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[21]  C. Cannon,et al.  Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes , 2015, Diabetes, obesity & metabolism.

[22]  M. Monami,et al.  Efficacy and safety of sodium glucose co‐transport‐2 inhibitors in type 2 diabetes: a meta‐analysis of randomized clinical trials , 2014, Diabetes, obesity & metabolism.

[23]  W. White,et al.  Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. , 2014, Journal of the American Society of Hypertension : JASH.

[24]  C. Horikawa,et al.  Meta-analysis of the quantitative relation between pulse pressure and mean arterial pressure and cardiovascular risk in patients with diabetes mellitus. , 2014, The American journal of cardiology.

[25]  U. Broedl,et al.  The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus , 2014, Cardiovascular Diabetology.

[26]  E. O’Brien,et al.  Double product reflects the predictive power of systolic pressure in the general population: evidence from 9,937 participants. , 2013, American journal of hypertension.

[27]  S. Laurent,et al.  Large Artery Stiffening and Remodeling Are Independently Associated With All-Cause Mortality and Cardiovascular Events in Chronic Kidney Disease , 2012, Hypertension.

[28]  K. Asayama,et al.  Predictive value for mortality of the double product at rest obtained by home blood pressure measurement: the Ohasama study. , 2012, American journal of hypertension.

[29]  Christodoulos Stefanadis,et al.  Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. , 2010, European heart journal.

[30]  P. Nilsson,et al.  Pulse pressure strongly predicts cardiovascular disease risk in patients with type 2 diabetes from the Swedish National Diabetes Register (NDR). , 2009, Diabetes & metabolism.

[31]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[32]  D. A. Kenny,et al.  The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. , 1986, Journal of personality and social psychology.